Biologic drugs for the treatment of hidradenitis suppurativa: an evidence-based review

Dermatol Clin. 2010 Jul;28(3):511-21, 523-4; quiz 522-3. doi: 10.1016/j.det.2010.03.012.

Abstract

There are various treatment options for hidradenitis suppurativa (HS), a recurrent and suppurative disease, but none is wholly satisfactory or effective. There have been many reports on the efficacy of biologic drugs for the treatment of HS; this article is an in-depth review of the published evidence on this topic. Because the current evidence is limited, randomized, double-blinded, placebo-controlled trials are needed to better elucidate the future of these drugs for the treatment of HS.

Publication types

  • Review

MeSH terms

  • Adalimumab
  • Adolescent
  • Adult
  • Alefacept
  • Anti-Bacterial Agents / therapeutic use
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Clinical Trials as Topic
  • Dermatologic Agents / adverse effects
  • Dermatologic Agents / therapeutic use*
  • Etanercept
  • Female
  • Hidradenitis Suppurativa / drug therapy*
  • Humans
  • Immunoglobulin G / adverse effects
  • Immunoglobulin G / therapeutic use*
  • Infliximab
  • Male
  • Middle Aged
  • Receptors, Tumor Necrosis Factor / therapeutic use*
  • Recombinant Fusion Proteins / adverse effects
  • Recombinant Fusion Proteins / therapeutic use*
  • Therapies, Investigational*
  • Young Adult

Substances

  • Anti-Bacterial Agents
  • Anti-Inflammatory Agents, Non-Steroidal
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Dermatologic Agents
  • Immunoglobulin G
  • Receptors, Tumor Necrosis Factor
  • Recombinant Fusion Proteins
  • Infliximab
  • Alefacept
  • Adalimumab
  • Etanercept
  • efalizumab